Split-dose Versus Single-dose Bowel Preparation for Colonoscopy
1 other identifier
interventional
180
1 country
1
Brief Summary
Colonoscopy is the current standard method for evaluation of colonic disorders such as colorectal cancer, IBD, polyps, and other conditions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 25, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedFirst Submitted
Initial submission to the registry
May 19, 2024
CompletedFirst Posted
Study publicly available on registry
May 23, 2024
CompletedMay 23, 2024
May 1, 2024
12 months
May 19, 2024
May 19, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
colon cleansing
to compare the efficacy of split-dose versus single morning administration of PEG solution for colon cleansing in patient undergoing colonoscopy using Boston Bowel Preparation Scale , and to assess the optimal preparation- to-colonoscopy (PC) interval .
2 hours before Bowel Preparation
Study Arms (2)
Split-dose bowel preparation
EXPERIMENTALAbout 90 participants underwent Split-dose bowel preparation for colonoscopy
single-dose bowel preparation
EXPERIMENTALAbout 90 participants underwent single-dose bowel preparation for colonoscopy
Interventions
to compare bowel cleanliness, compliance, tolerability, and patient satisfaction of a single regimen versus a split regimen for colonoscopy.
Eligibility Criteria
You may qualify if:
- \- All patients undergoing elective colonoscopy
You may not qualify if:
- Presence of sever renal impairment. (Creatinine clearance \< 30 ml/min or patient on hemodialysis).
- Sever congestive heart failure (NHYA III or IV).
- Pregnant woman.
- History of bowel obstruction or resection.
- Known allergies to polyethylene glycol.
- Refusal of consent for the study.
- Signs of liver cell failure as ascites and hepatic encephalopathy.
- Electrolytes disturbances
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Egymedicalpedialead
Study Sites (1)
Mansoura university Hospital
Al Mansurah, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Seham Mohammad Abd-AlAdl Seif, Professor
Internal Medicine Hepatology and Gastroenterology Faculty of Medicine - Mansoura University
- STUDY DIRECTOR
Hany Shabana, M.D
Hepatology and Gastroenterology Faculty of Medicine - Mansoura University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 19, 2024
First Posted
May 23, 2024
Study Start
November 1, 2022
Primary Completion
October 25, 2023
Study Completion
December 1, 2023
Last Updated
May 23, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share